An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action

• Published in: Investigational new drugs Vol. 15; no. 1; pp. 49 - 59
• Main Author: GRADISHAR, W. J
• Format: Journal Article
• Language: English
• Published: Dordrecht Kluwer 01.01.1997; Springer Nature B.V
• Subjects: Angiogenesis; Antibiotics, Antineoplastic - pharmacology; Antibiotics, Antineoplastic - therapeutic use; Antigens; Antineoplastic agents; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Binding sites; Biological and medical sciences; Blood; Blood vessels; Cancer therapies; Cell Division - drug effects; Cell growth; Chemotherapy; Clinical trials; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diabetic retinopathy; Drugs, Investigational - pharmacology; Drugs, Investigational - therapeutic use; Endothelium, Vascular - cytology; Endothelium, Vascular - drug effects; Enzyme Inhibitors - pharmacology; Enzyme Inhibitors - therapeutic use; Fibroblasts; Growth factors; Hemangioma; Humans; Interferon; Laboratories; Leukemia; Medical sciences; Metastasis; Molecular weight; Neoplasm Invasiveness - pathology; Neoplasms - blood supply; Neoplasms - drug therapy; Neoplasms - pathology; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - physiopathology; Neovascularization, Physiologic - drug effects; Pharmacology. Drug treatments; Physiology; Retinoids - therapeutic use; Tumors; Antineoplastic agent; Human; Angiogenic factor; Cytokine; Enzyme inhibitor; Octreotide; Review; Retinoids; Malignant tumor; Suramin sodium; Biological activity; Angiogenesis; Platelet factor 4; Pentosan polysulfate sodium; Clinical trial; Advanced stage; Inhibitor; Interferon; Mechanism of action; Thalidomide
• ISSN: 0167-6997; 1573-0646
• DOI: 10.1023/A:1005770612294

Angiogenesis is a biologic process whereby endothelial cells divide and migrate to form new blood vessels. This process is required in physiological conditions, but is also a necessary requirement for solid tumors to grow and metastasize. Over the last several years, the growth factors that have both a positive and negative influence on tumor angiogenesis have been delineated. Interfering with tumor angiogenesis was considered a potential therapeutic strategy 25 years ago, but only recently have compounds with an ability to interfere with angiogenesis entered clinical trials. This review will discuss the first generation of angiogenesis inhibitors, their mechanism of action and data from clinical trials.